SAN DIEGO, July 30, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (OTCQB: TCON) today announced that the Company has terminated its employees and will wind down its operations. This decision was made at a special meeting of the board of directors.
TRACON Pharmaceuticals, Inc. (NASDAQ:TCON ) Q1 2024 Earnings Conference Call is scheduled for May 14, 2024 at 4:30 PM ET. Presenting on the call will be Charles Theuer, President & CEO, and Scott Brown, CFO. Joining the call will be Matthew Venezia from Alliance Global Partners. Thank you for joining us today. Please note that all participants are currently in listen-only mode.
SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, announced today that it will report its fourth quarter and year-end 2023 financial and operating results after the close of U.S. financial markets on Tuesday, March 5, 2024. In addition, management will host a conference call to provide an update on corporate activities and discuss the financial results.
Tracon Pharmaceuticals (NASDAQ: TCON ) stock is rocketing higher on Tuesday as investors react to a licensing agreement for its product development platform ( PDP ). According to a press release from the company, it has licensed this to a clinical-stage biotech company for an upfront payment of $3 million.
Tracon Pharmaceuticals (NASDAQ: TCON ) stock is falling on Monday as the company's shares retreat from a massive rally on Friday. That rally saw shares of TCON stock climb 43.9% higher during normal trading hours.
Tracon Pharmaceuticals (NASDAQ: TCON ) stock is rocketing higher on Friday after the biopharmaceutical company announced results for the third quarter of 2023. Tracon Pharmaceuticals starts its report with adjusted earnings per share of 29 cents.
TRACON Pharmaceuticals, Inc. (NASDAQ:TCON ) Q3 2023 Results Conference Call November 9, 2023 4:30 PM ET Company Participants Dr. Charles Theuer - President and CEO Scott Brown - CFO Conference Call Participants Ed White - H.C. Wainwright Operator Good day, ladies and gentlemen, and welcome to TRACON Pharmaceuticals Third Quarter 2023 Earnings Conference Call.
SAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, announced today that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will participate at the following upcoming investor conferences and provide a company overview:
TRACON Pharmaceuticals, Inc. (NASDAQ:TCON ) Q2 2023 Earnings Call August 14, 2023 4:30 PM ET Company Participants Charles P. Theuer - President and CEO Scott B.
SAN DIEGO, Aug. 02, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, announced today that it will report its second quarter 2023 financial and operating results after the close of U.S. financial markets on Monday, August 14, 2023. In addition, management will host a conference call to provide an update on corporate activities and discuss the financial results.